R Castejon1, C Jimenez-Ortiz2, S Rosado3, P Tutor-Ureta3, S Mellor-Pita3, M Yebra-Bango3. 1. Systemic Autoimmune Diseases Unit, Internal Medicine Service, University Hospital Puerta de Hierro Research Institute, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain raquel.castejon@salud.madrid.org. 2. Neurology Service, University Hospital Puerta de Hierro Research Institute, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. 3. Systemic Autoimmune Diseases Unit, Internal Medicine Service, University Hospital Puerta de Hierro Research Institute, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
Abstract
OBJECTIVES: Metabolic syndrome (MetS) is highly prevalent in patients with systemic lupus erythematosus (SLE) and it has been associated with increased cardiovascular risk. We examined the contribution of MetS to inflammatory markers, arterial stiffness and circulating endothelial progenitor cells (EPCs) as surrogates of subclinical atherosclerosis. METHODS: Cardiovascular risk factors, SLE-specific factors and peripheral blood EPCs were assessed in 50 female SLE patients. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III. Simultaneously, atherosclerosis was assessed by measuring the carotid-femoral pulse wave velocity (PWV) by doppler velocimetry. RESULTS: Beyond the factors included in the definition, SLE patients with MetS have a significantly higher serum level of uric acid (6.88 ± 2.20 vs 4.45 ± 1.17, p < 0.001) and some inflammatory biomarkers such as homocysteine, IL-8, sICAM-1 or complement molecules. The presence of MetS in our patients was closely linked with a significantly increased patient organ damage score (3.20 ± 1.97 vs 1.60 ± 1.67, p = 0.008), a decreased percentage of circulating EPCs (0.53 ± 0.24 vs 0.85 ± 0.57, p = 0.007) and an increased arterial stiffness (9.89 ± 2.40 vs 7.13 ± 1.51, p < 0.001). CONCLUSIONS: MetS may contribute to the development of atherosclerosis by significantly increasing inflammation levels and arterial stiffness and decreasing circulating EPCs. This finding would justify close monitoring of these patients.
OBJECTIVES:Metabolic syndrome (MetS) is highly prevalent in patients with systemic lupus erythematosus (SLE) and it has been associated with increased cardiovascular risk. We examined the contribution of MetS to inflammatory markers, arterial stiffness and circulating endothelial progenitor cells (EPCs) as surrogates of subclinical atherosclerosis. METHODS: Cardiovascular risk factors, SLE-specific factors and peripheral blood EPCs were assessed in 50 female SLEpatients. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III. Simultaneously, atherosclerosis was assessed by measuring the carotid-femoral pulse wave velocity (PWV) by doppler velocimetry. RESULTS: Beyond the factors included in the definition, SLEpatients with MetS have a significantly higher serum level of uric acid (6.88 ± 2.20 vs 4.45 ± 1.17, p < 0.001) and some inflammatory biomarkers such as homocysteine, IL-8, sICAM-1 or complement molecules. The presence of MetS in our patients was closely linked with a significantly increased patient organ damage score (3.20 ± 1.97 vs 1.60 ± 1.67, p = 0.008), a decreased percentage of circulating EPCs (0.53 ± 0.24 vs 0.85 ± 0.57, p = 0.007) and an increased arterial stiffness (9.89 ± 2.40 vs 7.13 ± 1.51, p < 0.001). CONCLUSIONS: MetS may contribute to the development of atherosclerosis by significantly increasing inflammation levels and arterial stiffness and decreasing circulating EPCs. This finding would justify close monitoring of these patients.
Authors: Paola A Zeña-Huancas; Haydee Iparraguirre-López; Rocío V Gamboa-Cárdenas; Cristina Reátegui-Sokolova; Francisco Zevallos-Miranda; Mariela Medina-Chinchon; Victor R Pimentel-Quiroz; Claudia Elera-Fitzcarrald; Omar Sarmiento-Velasquez; Jorge M Cucho-Venegas; José L Alfaro-Lozano; Zoila J Rodríguez-Bellido; César A Pastor-Asurza; Risto A Perich-Campos; Graciela S Alarcón; Manuel F Ugarte-Gil Journal: Clin Rheumatol Date: 2018-12-12 Impact factor: 2.980
Authors: Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider Journal: J Rheumatol Date: 2019-08-01 Impact factor: 4.666
Authors: Peter Korsten; Daniel Patschan; Elvira Henze; Timothy B Niewold; Gerhard Anton Müller; Susann Patschan Journal: Lupus Sci Med Date: 2016-12-23